Current Trials


 Urologic Problem

 Primary Investigator


A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH). #178-MA-1008

Male Overactive Bladder

Michael Guralnick, MD

Open for enrollment

A Phase III, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Assess the Efficacy and Safety of One or More Intradetrusor Treatments of  600 or 800 Units of Dysport® for the Treatment of Urinary Incontinence in Subjects with Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis

Neurogenic Bladder

Corey O'Connor, MD Open for enrollment

Ex Vivo Thermoacoustic Imaging of Prostate Specimens for Cancer Localization

Prostate Cancer

Sarah Patch, PhD

Open for enrollment

MicroRNA Distribution along Human Nephrons Bank

Renal Cell Cancer

Mingyu Liang, PhD

Open for enrollment

Future studies:

  • Vaccine trial for renal cell cancer
  • Study for metastatic prostate cancer

Past studies:

  • Prostate cancer vaccines
  • Osteoporosis due to hormone therapy for prostate cancer
  • Prostate cancer prevention
  • Benign Prostatic Hyperplasia (BPH), Prostatitis
  • Treatment of hot flashes in Prostate Cancer Patients
  • Erectile Dysfunction
  • Testicular Prosthesis
  • Overactive Bladder/Incontinence
  • InTone Urinary Incontinence Device
  • HIFU (High Intensity Focused Ultrasound) Imaging for Prostate Cancer

For more information, please contact Heather Engelke at (414) 805-0785

Please note that our objective is to provide a current list of available clinical trials. A listing does not guarantee that a trial is open to enrollment, and there may be additional trials available that are not listed. Please contact your urologist or the research data coordinator number provided for complete information.